Seelos Therapeutics Liabilities 2024

Seelos Therapeutics Aktienanalyse

What does Seelos Therapeutics do?

Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. The company was founded in 2016 by Raj Mehra and is headquartered in New York City. Seelos Therapeutics Inc specializes in the development of therapeutics for neurological and psychiatric disorders, with a focus on treating patients with severe, chronic, or life-threatening conditions. The company has developed an innovative business model based on collaboration with various institutions, organizations, and companies. The company is divided into several divisions, including clinical development, product development, technology development, and strategic partnerships. Each division focuses on specific aspects of therapy development and contributes to Seelos' ability to develop innovative and effective therapeutics for its patients. In the clinical development division, Seelos Therapeutics Inc focuses on conducting clinical trials to assess the efficacy and safety of its therapeutics. The company works closely with various academic institutions and clinics to conduct its clinical studies and ensure they adhere to the highest scientific standards. The product development division is responsible for the development of Seelos' actual therapeutics. It encompasses research, development, manufacturing, and quality assurance of the company's products. Seelos emphasizes rigorous quality and safety management to ensure its products meet the highest standards. In the technology development division, Seelos focuses on developing innovative technologies for therapy development. In collaboration with various institutions and companies, the company invests in the development of new technologies to improve its therapeutics and optimize patient care. A crucial aspect of Seelos' business model is collaboration with other companies and institutions. The company has formed strategic partnerships with various institutions and companies in the biotechnology and pharmaceutical fields. This allows Seelos to leverage the expertise and resources of other companies and expedite the development of its therapeutics. Seelos' flagship product is SLS-002, a novel rapid-onset nasal ketamine for the treatment of suicidality in patients with depression and bipolar disorder. SLS-002 has shown promising results in clinical trials and is currently in Phase 2b of clinical development. Seelos is also working on the development of therapeutics for other neurological and psychiatric disorders, such as Huntington's disease, neuropathic pain, and Amyotrophic Lateral Sclerosis (ALS). Overall, Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. Through its innovative business model and collaboration with other companies and institutions, Seelos aims to expedite the development of its therapeutics and improve the lives of patients with severe, chronic, or life-threatening conditions. Seelos Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Seelos Therapeutics's Liabilities

Seelos Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Seelos Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Seelos Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Seelos Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Seelos Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Seelos Therapeutics stock

What is the level of liabilities of Seelos Therapeutics this year?

Seelos Therapeutics has a debt balance of 38.93 M USD this year.

What were the liabilities of Seelos Therapeutics compared to the previous year?

The liabilities of Seelos Therapeutics have increased by 16.7% increased compared to the previous year.

What are the consequences of high debt for investors of Seelos Therapeutics?

High liabilities can pose a risk for investors of Seelos Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Seelos Therapeutics?

Low liabilities mean that Seelos Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Seelos Therapeutics affect the company?

An increase in liabilities of Seelos Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Seelos Therapeutics affect the company?

A decrease in the liabilities of Seelos Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Seelos Therapeutics?

Some factors that can influence the liabilities of Seelos Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Seelos Therapeutics so important for investors?

The liabilities of Seelos Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Seelos Therapeutics take to modify the liabilities?

To change its liabilities, Seelos Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Seelos Therapeutics pay?

Over the past 12 months, Seelos Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seelos Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seelos Therapeutics?

The current dividend yield of Seelos Therapeutics is .

When does Seelos Therapeutics pay dividends?

Seelos Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seelos Therapeutics?

Seelos Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seelos Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seelos Therapeutics located?

Seelos Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seelos Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seelos Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Seelos Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Seelos Therapeutics in the year 2023?

In the year 2023, Seelos Therapeutics distributed 0 USD as dividends.

In which currency does Seelos Therapeutics pay out the dividend?

The dividends of Seelos Therapeutics are distributed in USD.